{"Ticker": "BSX", "Company": "Boston Scientific", "Sector": "Health Care", "Updated": "2023-03-29", "Rating": [{"Date": "2023-03-29", "Rating": "Initiated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": "$57"}, {"Date": "2022-12-22", "Rating": "Initiated", "Organization": "Mizuho", "Rating_Change": "Neutral", "Target_Change": "$52"}, {"Date": "2022-12-20", "Rating": "Resumed", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$54"}, {"Date": "2022-10-18", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$49"}, {"Date": "2022-10-12", "Rating": "Initiated", "Organization": "Jefferies", "Rating_Change": "Buy", "Target_Change": "$50"}, {"Date": "2022-07-06", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Outperform", "Target_Change": "$43"}, {"Date": "2022-05-27", "Rating": "Upgrade", "Organization": "Needham", "Rating_Change": "Hold to Buy", "Target_Change": "$48"}, {"Date": "2022-04-13", "Rating": "Resumed", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$52"}, {"Date": "2022-03-02", "Rating": "Resumed", "Organization": "BofA Securities", "Rating_Change": "Buy", "Target_Change": "$55"}, {"Date": "2021-12-10", "Rating": "Initiated", "Organization": "RBC Capital Mkts", "Rating_Change": "Outperform", "Target_Change": "$51"}, {"Date": "2021-05-26", "Rating": "Downgrade", "Organization": "Needham", "Rating_Change": "Buy to Hold", "Target_Change": ""}, {"Date": "2021-05-25", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$51"}, {"Date": "2021-04-15", "Rating": "Initiated", "Organization": "Atlantic Equities", "Rating_Change": "Overweight", "Target_Change": "$52"}, {"Date": "2020-09-17", "Rating": "Initiated", "Organization": "Truist", "Rating_Change": "Buy", "Target_Change": "$47"}, {"Date": "2020-09-11", "Rating": "Initiated", "Organization": "Wolfe Research", "Rating_Change": "Peer Perform", "Target_Change": "$46"}, {"Date": "2020-04-22", "Rating": "Downgrade", "Organization": "SVB Leerink", "Rating_Change": "Outperform to Mkt Perform", "Target_Change": "$40"}, {"Date": "2020-04-01", "Rating": "Upgrade", "Organization": "Goldman", "Rating_Change": "Neutral to Buy", "Target_Change": "$46 to $38"}, {"Date": "2020-03-05", "Rating": "Initiated", "Organization": "Citigroup", "Rating_Change": "Buy", "Target_Change": "$48"}, {"Date": "2020-02-13", "Rating": "Initiated", "Organization": "Goldman", "Rating_Change": "Neutral", "Target_Change": "$46"}, {"Date": "2020-02-06", "Rating": "Resumed", "Organization": "BTIG Research", "Rating_Change": "Buy", "Target_Change": "$46"}, {"Date": "2019-12-30", "Rating": "Reiterated", "Organization": "Cowen", "Rating_Change": "Outperform", "Target_Change": "$47 to $52"}, {"Date": "2019-12-19", "Rating": "Downgrade", "Organization": "Needham", "Rating_Change": "Strong Buy to Buy", "Target_Change": "$53"}, {"Date": "2019-09-05", "Rating": "Resumed", "Organization": "JP Morgan", "Rating_Change": "Overweight", "Target_Change": "$50"}, {"Date": "2019-09-03", "Rating": "Resumed", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$48"}, {"Date": "2019-05-13", "Rating": "Upgrade", "Organization": "Evercore ISI", "Rating_Change": "In-line to Outperform", "Target_Change": ""}, {"Date": "2018-11-28", "Rating": "Initiated", "Organization": "UBS", "Rating_Change": "Buy", "Target_Change": ""}, {"Date": "2018-10-16", "Rating": "Initiated", "Organization": "Barclays", "Rating_Change": "Overweight", "Target_Change": "$43"}, {"Date": "2018-10-02", "Rating": "Reiterated", "Organization": "Morgan Stanley", "Rating_Change": "Overweight", "Target_Change": "$38 to $48"}, {"Date": "2018-09-07", "Rating": "Reiterated", "Organization": "Needham", "Rating_Change": "Strong Buy", "Target_Change": "$39 to $43"}]}